SCHEMBL2736557

SCHEMBL2736557

Cc1cc(C(=O)NCCc2ccccc2)c(=O)n(C)c1C

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.57
CNR1 P21554 3/20 0.57
TP53 P04637 1/20 0.53
MAPT P10636 1/20 0.53
POLB P06746 2/20 0.52
LMNA P02545 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
HPGD P15428 2/20 0.51
USP2 O75604 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
RAB9A P51151 7/20 0.50
NPC1 O15118 6/20 0.50
BCL2 P10415 1/20 0.50
BCL2L1 Q07817 1/20 0.50
MCL1 Q07820 1/20 0.50
BCL2A1 Q16548 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2736556 0.87 CNR1 (0.70) CNR2CNR1TP53MAPTHTT
SCHEMBL5759224 0.85 CNR2 (0.68) CNR2CNR1TP53MAPTPOLB
SCHEMBL2736779 0.82 CNR2 (0.73) CNR2CNR1SMN1; SMN2HPGD
SCHEMBL2736774 0.79 CNR2 (0.54) CNR2CNR1TP53MAPTPOLB
SCHEMBL2736553 0.78 NPC1 (0.59) CNR2CNR1TP53MAPTPOLB
SCHEMBL2736555 0.78 CNR2 (0.52) CNR2CNR1TP53MAPTBCL2
SCHEMBL2736723 0.77 CNR2 (0.80) CNR2CNR1TP53MAPTPOLB
SCHEMBL2736714 0.77 CNR2 (0.70) CNR2CNR1TP53MAPTPOLB
SCHEMBL22639676 0.77 RAB9A (0.56) CNR2CNR1MAPTPOLBLMNA
SCHEMBL2736550 0.77 L3MBTL1 (0.60) CNR2CNR1TP53MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 US disclosed
US-20070027144-A1 Novel use of cannabinoid receptor agonist SHIONOGI & CO., LTD. (JP) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027144-A1 Novel use of cannabinoid receptor agonist CNR2, CNR1, OPRM1 CNR2 1/4885CNR1 2/4885TP53 4795/4885
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R CNR2 1/4885CNR1 2/4885TP53 4820/4885
US-20080312292-A1 Antipruritics CNR1, CNR2, OPRL1 CNR2 2/4885CNR1 1/4885TP53 4881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.